These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 4030547)

  • 1. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of anaerobic bacteria to Sch 34343 and other antibiotics.
    Glupczynski Y; Gordts B; van der Linden MP; Labbé M; Yourassowsky E; Butzler JP
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():193-8. PubMed ID: 4030548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in-vitro activity of Sch 34343 for a wide spectrum of clinically significant anaerobic bacteria.
    Wells CL; Wilkins TD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():177-82. PubMed ID: 4030546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro activity of Sch 34343 and other antimicrobial agents against anaerobic bacteria.
    Nord CE; Olsson-Liljequist B
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():183-8. PubMed ID: 2863246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaerobic bacteria and beta-lactam antibiotics.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 42():72-82. PubMed ID: 6335601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of Sch 34343 against anaerobic bacteria.
    Wexler H; Carter WT; Finegold SM
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():173-6. PubMed ID: 3861606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of SCH 34343 against anaerobic bacteria.
    Sutter VL; Wexler H; Finegold SM
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):341-4. PubMed ID: 3698546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
    Jacobs MR; Spangler SK; Appelbaum PC
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1081-93. PubMed ID: 1295763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Mar; 32(3):403-6. PubMed ID: 3364960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.
    Shafran SD; Wong J; Chow AW
    Antimicrob Agents Chemother; 1985 May; 27(5):749-52. PubMed ID: 4015069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of anaerobic bacteria to imipenem.
    Tally FP; Jacobus NV
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():47-51. PubMed ID: 6583197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of anaerobic bacteria to cefoperazone and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Barza M; Gorbach SL
    Clin Ther; 1980; 3(Spec Issue):34-8. PubMed ID: 6446396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of faropenem against 579 strains of anaerobic bacteria.
    Wexler HM; Molitoris D; St John S; Vu A; Read EK; Finegold SM
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3669-75. PubMed ID: 12384389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of imipenem against anaerobic bacteria.
    Wexler HM; Finegold SM
    Rev Infect Dis; 1985; 7 Suppl 3():S417-25. PubMed ID: 3901206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of anaerobic bacteria to antimicrobial agents.
    Collignon PJ; Munro R; Morris G
    Pathology; 1988 Jan; 20(1):48-52. PubMed ID: 3374973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial activity of ornidazole and 6 other antibiotics against anaerobic bacteria].
    Alados JC; Martínez-Brocal A; Miranda C; Rojo MD; García V; Domínguez MC; de la Rosa M
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):219-22. PubMed ID: 1863621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in susceptibility to latamoxef(moxalactam) and cefoxitin within the Bacteroides fragilis group.
    Eley A; Greenwood D
    J Antimicrob Chemother; 1984 Mar; 13(3):245-55. PubMed ID: 6725175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.